RESEARCH-USE BIOSIMILAR ANTIBODY
Bemarituzumab
Monoclonal antibody · IgG1
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer.
TARGETFGFR2
YMonoclonal antibody
CATALOGSC-BS-727
CATALOG NUMBERSC-BS-727
MOLECULAR WEIGHTApprox. 143.86 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer.
Bemarituzumab is a recombinant research-use antibody directed against FGFR2.